Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Mevo Health vs Queen RX

Mevo Health
Graded #326

Lower grade

vs+6.099999999999994
Queen RX
Graded #192

Higher grade

The verdict

Queen RX takes it — 66.3/100 to 60.2/100.

Queen RX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Queen RX offers compounded GLP-1 treatment (semaglutide, tirzepatide, liraglutide) at $299/quarter (~$100/mo).

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueQueen RX +21
56
77
Dose & formulationMevo Health +26
83
57
Clinical oversightQueen RX +2
67
69
Labs & monitoringQueen RX +1
52
53
FulfillmentQueen RX +18
57
75
Contract termsQueen RX +41
20
61
Mevo Health · left barQueen RX · right bar

The numbers

MetricMevo HealthQueen RX
WeighScore60.2/10066.3/100
GradeCC
Scorecard rank#326#192
Semaglutide$199/mo (all doses, compounded)$100/mo (quarterly plan, compounded)
Tirzepatide$259/mo (all doses, compounded)Not disclosed
CoverageCoverage not published45 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesInjection only
Mevo Health

Graded #326 · C

Strengths

  • LegitScript verification badge on multiple pages
  • Publishes the FDA compounded-medication disclaimer
  • Four named board-certified physicians disclosed (Wasef, Suppa, Sakla, Chikando)
  • Both semaglutide and tirzepatide in injection and oral-tablet forms — rare in DTC
  • Public entry-level pricing surfaced

Where it loses points

  • States served not listed on any public page
  • Pharmacy partners not named (only '503A U.S. compounding pharmacies' with unlabeled logos)
  • No formal Medical Director role disclosed
  • Only 'as low as' entry pricing shown — no per-dose itemization
  • No SOC 2 certification claimed
Queen RX

Graded #192 · C

Strengths

  • $299/quarter (~$100/mo) — among the lowest GLP-1 pricing in the dataset
  • Three GLP-1 options: semaglutide, tirzepatide, and liraglutide
  • 45-state coverage

Where it loses points

  • No LegitScript or PCAB accreditation
  • No legal entity name or address disclosed
  • No named pharmacy partners
  • Not available in KS, LA, MS, NM, WV

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard